tiprankstipranks

Barry Quart Insider Profile

4 Followers
Barry Quart, CEO, Director at Heron Therapeutics, holds 177.99K shares in Heron Therapeutics (Ticker: HRTX), holds 5.00K shares in Kiniksa Pharmaceuticals (Ticker: KNSA), holds 0.00 shares in Synageva (Ticker: GEVA).
tipranks
Barry Quart

Barry Quart
Heron Therapeutics (HRTX)
CEO, Director

Ranked #68,510 out of 97,825 Corporate Insiders

Profitable Transactions

22%
2 out of 9 Profitable Transactions

Average Return

-8.10%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$588K
82.99%
17.01%
A breakdown of Barry Quart's holdings

Insider Roles

Heron Therapeutics
(HRTX)
CEO, Director
Kiniksa Pharmaceuticals
(KNSA)
Director
Roles that Barry Quart holds in companies

Most Profitable Insider Trade

Stock:
Heron Therapeutics
(HRTX)
Rating:Informative Buy
Date:Jun 26, 2014 - Jun 26, 2015
Return:+154.70%
The most profitable trade made by Barry Quart

Barry Quart's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Heron Therapeutics
Jan 17, 2023
CEO, Director
Uninformative Buy
5.41K
$487.69K
Kiniksa Pharmaceuticals
Dec 01, 2022
Director
Informative Sell
354.64K
$99.95K
GEVA
Synageva
Jun 24, 2014
Uninformative Sell
137.50K
List of latest transactions for each holding click on a transaction to see Barry Quart's performance on stock

Barry Quart insider profile FAQ

What is the percentage of profitable transactions made by Barry Quart?
The percentage of profitable transactions made by Barry Quart is 22%.
    What is the average return per transaction made by Barry Quart?
    The average return per transaction made by Barry Quart is -8.10%.
      What stocks does Barry Quart hold?
      Barry Quart holds: HRTX, KNSA, GEVA stocks.
        What was Barry Quart’s latest transaction?
        Barry Quart latest transaction was an Uninformative Buy of $5.41K.
          What was Barry Quart's most profitable transaction?
          Barry Quart’s most profitable transaction was an Informative Buy of HRTX stock on June 26, 2014. The return on the trade was 154.70%.
            What is Barry Quart's role in Heron Therapeutics?
            Barry Quart's role in Heron Therapeutics is CEO, Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.